Status:
RECRUITING
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Conditions:
Squamous Cell Carcinoma of the Oropharynx
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Epidermoid Carcinoma of the Upper Aerodigestive Tract (CEVADS) is the 6th most common cancer worldwide. Despite current therapies (radiotherapy, surgery and chemotherapy), cancers of the Upper Aerodig...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years
- Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx
- Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy
- Patient affiliated to a health insurance plan
- French-speaking patient
- Patient with free, informed and written consent
Exclusion
- Patients with a contraindication to immunotherapy (transplant patients)
- Pregnant or breast-feeding patients
- Patient under guardianship or curatorship
- Patient under court protection
- Patient deprived of liberty
Key Trial Info
Start Date :
January 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06061705
Start Date
January 29 2024
End Date
June 30 2026
Last Update
June 24 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Saint-Joseph
Paris, France, 75014
2
Hôpital Bichat
Paris, France
3
Hôpital Saint-Louis
Paris, France